Асосий контентга ўтиш
AkademIndex

Хизматлар

← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

186 та иш

Иш: Outsmarting Antigen Escape: Next‐Generation <scp>CAR</scp> T Cell Engineering Strategies for Durable Remissions in Hematologic Malignancies

  1. Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect

    Chengcheng Feng, Yuting Wang, Jinghua Xu +5

    Мақола202412 иқтибос
    ABI

  2. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies

    Ding-Ya Sun, Yijie Hu, Xin Li +3

    Шарҳ мақола202411 иқтибос
    ABI

  3. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Шарҳ мақола20259 иқтибос
    ABI

  4. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Мақола20238 иқтибос
    ABI

  5. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers

    Wei-Xin Xu, Qiang Qu, Hai-Hui Zhuang +5

    Мақола20247 иқтибос
    ABI

  6. CAR-T cell therapy for cancer: current challenges and future directions

    Inés Zugasti, Lady Espinosa-Aroca, Klaudyna Fidyt +7

    Шарҳ мақола20257 иқтибос
    ABI

  7. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje, Jesús G. Berdeja, Yi Lin +20

    Мақола20195 иқтибос
    ABI

  8. CAR-T cell therapy: current limitations and potential strategies

    Robert C. Sterner, Rosalie M. Sterner

    Шарҳ мақола20215 иқтибос
    ABI

  9. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy

    Alireza Bayani, Munthar Kadhim Abosaoda, Jasur Rizaev +3

    Шарҳ мақолаAdvanced biosensing and bioanalysis techniquesClinical and Experimental Medicine20254 иқтибос
    ABI

  10. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

    Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

    Мақола20174 иқтибос
    ABI

  11. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Мақола20184 иқтибос
    ABI

  12. Engineering and Design of Chimeric Antigen Receptors

    Sònia Guedan, Hugo Calderón, Avery D. Posey +1

    Шарҳ мақола20184 иқтибос
    ABI

  13. Сарлавҳасиз

    Бошқа4 иқтибос
    ABI

  14. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

    Margot J. Pont, Tyler Hill, Gabriel O. Cole +14

    Мақола20193 иқтибос
    ABI

  15. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

    Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

    Мақола20213 иқтибос
    ABI

  16. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  17. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

    Gils Roex, Diana Campillo-Davó, Donovan Flumens +6

    Мақола20223 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  19. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors

    Koichi Hirabayashi, Hongwei Du, Yang Xu +8

    Мақола20213 иқтибос
    ABI

  20. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape

    You Zhai, Yicong Du, Guanzhang Li +9

    Мақола20233 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа3 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа2 иқтибос
    ABI